Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1104-1112

  Lampen, Alfonso ^a   Zhang, Yuanchao ^b   Hackbarth, Ina ^c   Benet, Leslie Z ^b   Sewing, Karl Fr ^c   Christians, Uwe ^b,d  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CORTICOSTERONE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 3A; DEXAMETHASONE; DRUG METABOLITE; ERGOTAMINE; ERYTHROMYCIN; ETHINYLESTRADIOL; JOSAMYCIN; KETOCONAZOLE; MACROLIDE; METHYLPREDNISOLONE; MICONAZOLE; NIFEDIPINE; RAPAMYCIN; TACROLIMUS; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ANALYSIS; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MICHAELIS CONSTANT; MICROSOME; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE MUCOSA;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MICROSOMES; OXIDOREDUCTASES, N-DEMETHYLATING; POLYENES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SWINE;

EID: 0031863355     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Bargetzi MJ, Aoyama T, Gonzalez FJ and Meyer UA (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46:521-527.
2. Benet LZ, Wu C-Y, Herbert MF and Wacher VJ (1996) Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Control Release 39:139-143.
3. Birkett DJ, Mackenzie PI, Veronese ME and Miners JO (1994) In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 141:292-294.
4. Chang T, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetylolenadomycin, α-naphtoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P-450. Arch Biochem Biophys 311:437-442.
5. Christians U, Sattler M, Schiebel HM, Kruse C, Radeke HH, Linck A and Sewing KF (1992) Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 20:186-191.
6. Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A and Sewing KF (1996) Identification of drugs inhibiting the the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 41:187-190.
7. Department of Health and Human Services US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research (1997) Guidance for the industry: Drug metabolism/drug interaction studies in the drug development process: Studies in vitro.
8. Estabrook RW and Werringloer J (1978) The measurement of difference spectra: Application to the cytochromes of microsomes. Methods Enzymol 52:212-220.
9. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP and Hebert MF (1997) The effects of ketoconazole on the pharmacokinetic disposition of tacrolimus. Clin Pharmacol Ther 62:41-49.
10. Gorski JC, Hall SD, Jones DR, Vandenbranden M and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
11. Guengerich FP (1982) Microsomal enzymes involved in toxicology: Analysis and separation. In Principles and Methods of Toxicology, ed. by Hayes AW, pp. 609-637, Raven Press, New York.
12. Guengerich FP (1992) Characterization of human P450 enzymes. FASEB J 6:745-748.
13. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
14. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
15. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
16. Kolars JC, Stetson PL, Rush BD, Ruwart MJ, Schmiedlin-Ren P, Duell EA, Voorhees JJ and Watkins PB (1992) Cyclosporin A metabolism by P450IIIA in rat enterocytes: Another determinant of oral bioavailability? Transplantation 53:596-602.
17. Kuhnt M, Bitsch F, Ponelle M, Fehr T and Sanglier JJ (1997) Microbial conversion of rapamycin. Enzyme Microbiol Technol 21:405-412.
18. Lampen A, Christians U, Guengerich FP, Watkins P, Kolars JC, Bader A, Dralle H, Hackbarth I and Sewing KF (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 23:1315-1324.
19. Lampen A, Christians U, Bader A, Hackbarth I and Sewing KF (1996a) Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 52:159-168.
20. Lampen A, Christians U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W and Sewing K-Fr (1996b) Metabolism of the macrolide immunosuppressant tacrolimus by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730-1734.
21. 14C]-rapamycin (sirolimus) in healthy male subjects after a single dose. ISSX Proc 12:26.
22. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA and Watkins PB (1994) Interpatient heterogeneity in expression of cyp3A4 and cyp3A5 in small bowell. Drug Metab Dispos 22:947-952.
23. Murray M and Reidy GF (1990) Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42:85-101.
24. Napoli KL, Wang ME, Stepkowski SM and Kahan BD (1997) Distribution of sirolimus in rat tissue. Clin Biochem 30:135-142.
25. Ochs HR, Greenblatt DJ, Eichelkraut W, Bakker C, Göbel R and Hahn N (1987) Hepatic us. gastrointestinal presystemic extraction of oral midazolam and flurazepam. J Pharmacol Exp Ther 243:852-856.
26. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
27. Peters DH, Fitton A, Plosker GL and Faulds D (1993) Tacrolimus: A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 46:746-794.
28. Pichard L, Fabre I, Fabre G, Domerque J, Saint Aubert B, Mourad G and Maurel P (1990) Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and liver microsomes. Drug Metab Dispos 18:595-606.
29. Pinkus LM (1981) Separation and use of enterocytes. In Methods in Enzymology, ed. by Jakoby WB, vol. 77, pp. 154-162, Academic Press, New York.
30. Porteous JW, Furneaux HM, Pearson FK, Lake CM and Morison A (1979) Poly adenosine diphosphate ribose synthetase activity in nuclei of dividing but differentiating intestinal epithelial cells. Biochem J 180:455-463.
31. Sattler M, Guengerich FP, Yun CY, Christians U and Sewing KF (1992) Cytochrome P-4503A4 is responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761.
32. Shapiro JAM, Gallant HL, Wong EHJ, Rajotte R, Yatscoff RW and Kneteman NM (1997) Differences in portal and systemic blood pharmacokinetics after oral dosing of immunosuppressants. Ther Drug Monit 19:553.
33. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
34. Stepkowski SM, Napoli KL, Wang M-E, Qu X, Chou T-C and Kahan BD (1996) Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 62:986-994.
35. Streit F, Christians U, Schiebel H-M, Meyer A and Sewing KF (1996a) Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray MS/MS after incubation with human liver microsomes. Drug Metab Dispos 24:1272-1278.
36. Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, Kahan BD and Sewing K F (1996b) Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 42:1417-1425.
37. Wacher VJ, Salphati L and Benet LZ (1996) Active secretion and enterocyte drug metabolism barriers to drug absorption. Adv Drug Delivery Rev 20:99-112.
38. Wacher VJ, Wu C-Y and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13:129-134.
39. Wang CP, Chan KW, Schikanis RA, Scatina J and Sisenwine SF (1994) High-performance liquid chromatographic isolation, spectroscopic characteristics, and immunosuppressive activities of two rapamycin degradation products. J Liq Chromatogr 17:3383-3392.
40. Wang CP, Lim H-K, Chan KW, Scatina J and Sisenwine SF (1995) High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally. J Liq Chromatogr 18:2559-2568.
41. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
42. Yatscoff RW, Wang P, Chan K, Hicks D and Zimmermann J (1995) Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17:666-671.
43. Yee GC and McGuire TR (1990) Pharmacokinetic drug interactions with cyclosporin (part I). Clin Pharmacokinet 19:319-332.
44. Zimmerman JJ and Kahan BD (1997) Pharmacokinetics of sirolimus in stable renal ransplant patients after multiple oral dose administration. J Clin Pharmacol 37:405-415.